Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

(2015) V Goede et al.   LEUKEMIA

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

(2014) N. Pflug et al.   BLOOD

Diagnostic and Treatment Dilemma of Dual Pathology of Lung Cancer and Disseminated Tuberculosis

(2014) Nishitha Shetty et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneity of young and aged murine hematopoietic stem cells revealed by quantitative clonal analysis using cellular barcoding

(2013) E. Verovskaya et al.   BLOOD

High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia

(2013) Cheng Fang et al.   CANCER SCIENCE

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

(2010) Michaela Patz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients

(2008) Constantine S. Tam et al.   BRITISH JOURNAL OF HAEMATOLOGY